IP Library Granted Patent US 8,372,424
Granted Patent B2
US 8,372,424 · App. 13/596,971 · Granted Feb 12, 2013

Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,372,424
App. No.
13/596,971
Granted
Feb 12, 2013
Kind
B2
Abstract

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 −7 reciprocal second.

Claims (28)

1. A beneficial agent formulation, comprising:

a stable non-aqueous single phase biocompatible viscous vehicle, comprising a solvent component and a polymer component, wherein (i) the solvent component is lauryl lactate or lauryl alcohol, (ii) the polymer component is polyvinylpyrrolidone, and (iii) the viscous vehicle has a viscosity of about 10,000 to about 250,000 poise at 37° C.; and

particles, comprising a beneficial agent, wherein the particles are uniformly suspended in the vehicle.

2. The formulation of claim 1 , wherein the vehicle further comprises a surfactant component, wherein the surfactant component is glycerol monolaurate or a polysorbate.

3. The formulation of claim 1 , wherein the vehicle comprises the solvent component and the polymer component in a ratio of between 40:60 to 60:40.

4. The formulation of claim 1 , further comprising an antioxidant.

5. The formulation of claim 4 , wherein the antioxidant is selected from the group consisting of tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, and propyl gallate.

6. The formulation of claim 1 , comprising at least about 0.1% (w/w) beneficial agent.

7. The formulation of claim 1 , comprising at least about 10% (w/w) beneficial agent.

8. The formulation of claim 1 , wherein the beneficial agent is a peptide or protein.

9. The formulation of claim 8 , wherein the beneficial agent is a protein.

10. The formulation of claim 1 , wherein the formulation is stable at 65° C. for at least about 2 months.

11. The formulation of claim 1 , wherein the formulation is stable at 37° C. for at least about 3 months.

12. The formulation of claim 1 , wherein the formulation is stable at 37° C. for at least about one year.

13. The formulation of claim 1 , wherein the particles are prepared by spray-drying.

14. The formulation of claim 13 , wherein the particles further comprise a sugar.

15. The formulation of claim 14 , wherein the sugar is sucrose or mannitol.

16. The formulation of claim 1 , wherein the formulation further comprises a surfactant component.

17. The formulation of claim 16 , wherein the vehicle components are in a range of about 5% (w/w) to about 60% (w/w) for the solvent component, about 5% (w/w) to about 40% (w/w) for the surfactant component, and about 5% (w/w) to about 60% (w/w) for the polymer component.

18. A method of making the formulation of claim 1 , comprising:

mixing the vehicle and the particles to obtain the formulation.

19. A method of making the formulation of claim 1 , comprising:

heating the solvent and the polymer;

mixing the solvent and the polymer until the single phase vehicle is obtained;

heating the vehicle and mixing the vehicle and particles to obtain the formulation; and

allowing the formulation to cool.

20. The method of claim 19 , further comprising applying a vacuum while mixing the solvent and the polymer.

21. The method of claim 20 , further comprising applying a vacuum while mixing the vehicle and the particles.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
Reel/Frame 052433/0001 →
RELEASE OF SECURITY INTEREST Recorded Jan 29, 2020
From: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 051739/0453 →
SECURITY INTEREST Recorded Oct 23, 2019
From: INTARCIA THERAPEUTICS, INC.
To: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT
Reel/Frame 050801/0267 →
SECURITY INTEREST Recorded Oct 9, 2019
From: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050673/0020 →
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2015
From: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 036942/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2013
From: BERRY, STEPHEN A.; FEREIRA, PAMELA J.; DEHNAD, HOUDIN; MUCHNIK, ANNA
To: ALZA CORPORATION
Reel/Frame 031768/0978 →
LICENSE AGREEMENT Recorded Dec 10, 2013
From: ALZA CORPORATION
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 031793/0475 →
SECURITY AGREEMENT Recorded Nov 14, 2012
From: INTARCIA THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029299/0678 →